It should be noted that there are case reports of children with primary FSGS achieving remissions following treatment with TNFα inhibitors [37,38,39] and that TNFα pathway activation is a factor in a subset of FSGS and patients with minimal change disease with poor clinical outcomes [40]. Here, TNF is linked to focal segmental glomerulosclerosis.